Cognitive dysfunction and metabolic comorbidities in mood disorders: A repurposing opportunity for glucagon-like peptide 1 receptor agonists?
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Major depressive disorder and bipolar disorder are highly prevalent and disabling conditions. Cognition is considered a core domain of their psychopathology and a principle mediator of psychosocial impairment, disproportionately accounting for overall illness‐associated costs. There are few interventions with replicated evidence of efficacy in treating cognitive deficits in mood disorders. Evidence also indicates that cognitive deficits are associated with obesity and involve significant impairment across multiple domains. Conversely, weight‐loss interventions, such as physical exercise and bariatric surgery, have been shown to beneficially affect cognitive function. This convergent phenomenology suggests that currently available agents that target metabolic systems may also be capable of mitigating deficits in cognitive functions, and are, therefore, candidates for repurposing. The incretin glucagon‐like peptide‐1 (GLP‐1) is a hormone secreted by intestinal epithelial cells. GLP‐1 receptors (GLP‐1R) are widely expressed in the central nervous system. Activation of GLP‐1R leads to facilitation of glucose utilization and antiapoptotic effects in various organs. Pre‐clinical trials have demonstrated significant neuroprotective effects of GLP‐1, including protection from cell death, promotion of neuronal differentiation and proliferation; and facilitation of long‐term potentiation. Liraglutide is a GLP‐1R agonist that has been approved for the treatment of type 2 diabetes mellitus and obesity. Convergent preclinical and clinical evidence, including a proof‐of‐concept pilot study from group, has suggested that liraglutide may improve objective measures of cognitive function in adults with mood disorders. The safety and availability of GLP‐1R agonists indicate that they are promising candidates for repurposing, and that they may be viable therapeutic options for mood disorders. This article is part of the Special Issue entitled ‘Metabolic Impairment as Risk Factors for Neurodegenerative Disorders.’ HighlightsCognition is a principle mediator of psychosocial impairment in mood disorders and associated with metabolic disorders.Available agents that target metabolic systemsmay be capable of mitigating cognitive deficits.Liraglutide, a GLP‐1R agonist is approved for the treatment of type 2 diabetes mellitus and obesity.A recent proof‐of‐concept study reported significant improvements on cognitive function with liraglutide in mood disorders.The safety and availability of GLP‐1R agonistsindicate that they may be viable therapeutic options for mood disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overweight, Obesity, and Depression: A Systematic Review and Meta-analysis of Longitudinal Studies
Luppino, F. S., de Wit, L. M., Bouvy, P. F., Stijnen, T., Cuijpers, P., Penninx, B. W. J. H., & Zitman, F. G. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.2 · Cited by 4,322
Niendam, T. A., Laird, A. R., Ray, K. L., Dean, Y. M., Glahn, D. C., & Carter, C. S. (2012) · Cognitive, Affective, & Behavioral Neuroscience · doi:10.3758/s13415-011-0083-5 · Cited by 1,700 · cited 1×
“Cognitive dysfunction is thought to be subserved by abnormalities in distributed brain circuits (Snyder, 2013; Collette et al., 2006; Niendam et al., 2012).”
BackgroundSnyder, H. R. (2013) · Psychological Bulletin · doi:10.1037/a0028727 · Cited by 1,667
The Economic Burden of Depression in the United States: How Did It Change Between 1990 and 2000?
Greenberg, P. E., Kessler, R. C., Birnbaum, H. G., Leong, S. A., Lowe, S. W., Berglund, P. A., & Corey-Lisle, P. K. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1211 · Cited by 1,280 · cited 1×
“…and disability, independently of concurrent mood symptoms (Depp et al., 2012; Iosifescu, 2012;McIntyre et al., 2013a; Andreou and Bozikas, 2013), and to disproportionately account for overall illness-associated costs (Greenberg et al., 2003; Kessler et al., 2008; Kleine-Budde et al., 2014).”
BackgroundVancampfort, D., Stubbs, B., Mitchell, A. J., De Hert, M., Wampers, M., Ward, P. B., Rosenbaum, S., & Correll, C. U. (2015) · World Psychiatry · doi:10.1002/wps.20252 · Cited by 1,271
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
Geddes, J. R., & Miklowitz, D. J. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60857-0 · Cited by 848
Lawrence, D., Hancock, K. J., & Kisely, S. (2013) · BMJ · doi:10.1136/bmj.f2539 · Cited by 819 · cited 1×
“Underscoring the lack of progress in this area is data from epidemiological studies, which have documented that the aforementioned gap in life expectancy between individuals with a mood disorders and the general population has increased in the past decades (Osby et al., 2016; Lawrence et al., 2013).”
BackgroundBidirectional Association Between Depression and Metabolic Syndrome
Pan, A., Keum, N., Okereke, O. I., Sun, Q., Kivimaki, M., Rubin, R. R., & Hu, F. B. (2012) · Diabetes Care · doi:10.2337/dc11-2055 · Cited by 772
Cited by
McIntyre, R. S., Mansur, R. B., Rosenblat, J. D., & Kwan, A. T. H. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2295397 · Cited by 126
Self-citationGlucagon-like peptide 1 agonist and effects on reward behaviour: A systematic review
Badulescu, S., Tabassum, A., Le, G. H., Wong, S., Phan, L., Gill, H., Llach, C.-D., McIntyre, R. S., Rosenblat, J., & Mansur, R. (2024) · Physiology & Behavior · doi:10.1016/j.physbeh.2024.114622 · Cited by 90
Self-citationDetka, J., & Głombik, K. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00274-8 · Cited by 79
The pleiotropic of GLP-1/GLP-1R axis in central nervous system diseases
Zhang, L., Zhang, W., & Tian, X. (2023) · International Journal of Neuroscience · doi:10.1080/00207454.2021.1924707 · Cited by 54
Metadata
- Authors
- Mansur, R. B., Lee, Y., Subramaniapillai, M., Brietzke, E., & McIntyre, R. S.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 136
- Issue
- Pt B
- Pages
- 335-342
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W2789918798
- Cited by
- 47
- References
- 41
- FWCI
- 2.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cognitive dysfunction and metabolic comorbidities in mood disorders: A repurposing opportunity for glucagon-like peptide 1 receptor agonists? https://app.cochat.ai/papers/10.1016/j.neuropharm.2018.01.048
- The paper
- Mansur, R. B., Lee, Y., Subramaniapillai, M., Brietzke, E., & McIntyre, R. S. (2018). Cognitive dysfunction and metabolic comorbidities in mood disorders: A repurposing opportunity for glucagon-like peptide 1 receptor agonists? Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2018.01.048
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.